In a sub-study of the ARISTOTLE trial, higher levels of Apolipoprotein A1 were independently associated with a lower composite risk of ischaemic stroke, systemic embolism, myocardial infarction, and cardiovascular mortality.163. The gene discussed is APOA1; the disease is ischemic stroke.